Description of High Density Lipoprotein (HDL) Levels and the Risk of Atherosclerosis in Patient Aged>50 Years
DOI:
10.29303/jbt.v26i4.12805Published:
2026-10-23Downloads
Abstract
Atherosclerosis is a chronic progressive disease that remains the leading cause of death and disability worldwide, with a sharply increased risk in individuals over 50 years of age. High-density lipoprotein (HDL) is known as "good cholesterol" that plays a role in protecting blood vessels through reverse cholesterol transport, as well as antioxidant, anti-inflammatory, and antithrombotic properties. However, the association between HDL levels and atherosclerosis risk in the older age group still requires further understanding. To describe the profile of high-density lipoprotein (HDL) levels and atherosclerosis risk in patients aged >50 years at RS QIM Batang. This descriptive study used secondary data from medical records of 25 patients aged >50 years who underwent lipid profile examination. Samples were selected using purposive sampling technique. Analyzed data included total cholesterol, triglyceride, HDL, and LDL levels, as well as the LDL/HDL ratio, presented in the form of frequency distribution tables, percentag kues, and descriptive statistical values. HDL levels of the subjects ranged from 7–57 mg/dL, with a mean of 37.2 mg/dL. A total of 56% of patients had normal HDL levels, 36% had low levels, and only 8% had high levels. The mean LDL level was 115.0 mg/dL, with 80% of patients within the normal limit, while the mean LDL/HDL ratio reached 3.2. Total cholesterol levels ranged from 95–257 mg/dL (mean 191.9 mg/dL) and triglycerides from 63–630 mg/dL (mean 222.6 mg/dL). Most patients aged >50 years had normal HDL levels, yet more than one third showed decreased HDL levels, which may increase atherosclerosis risk. The mean LDL/HDL ratio also indicates a tendency toward a relatively high risk in this age group.
Keywords:
Atherosclerosis Age >50 Years High-Density Lipoprotein Lipid ProfileReferences
Abdellatif, M., Rainer, P. P., & Kroemer, G. (2023). Hallmarks of cardiovascular ageing. Nature Reviews Cardiology, 20, 754–777. https://doi.org/10.1038/s41569-023-00881-3
Andrade, C. (2020). The Inconvenient Truth About Convenience and Purposive samples. Journal of Psychological Medicine, 43(1), 86–88. https://doi.org/10.1177/0253717620977000
Boren, J., Chapman, J. M., Krauss, R. M., Packard, C. J., & Bentzon, J. F. (2020). Low-desnity Lipoproteins cause Atherosclerotic Cardiovaskular Disease: Pathophysiological, Genetic, and Therapeutic Insights. European Heart Journal, 41(24), 2313–2330. https://doi.org/10.1093/eurheartj/ehz962
Boren, J., & Williams, K. (2016). The central Role of Arterial Retention of Cholesterol-rich Apoliporpotein-B-containing Lipoproteins in the Pathogenesis of Atherosclerosis. Current Opinion in Lipidology, 27(5), 473–483. https://pubmed.ncbi.nlm.nih.gov/?term=Boren+Williams+arterial+retention+apoliporotein+B+atherosclerosis
Campbell, S., Greenwood, M., Prior, S., Shearer, T., & Walkem, K. (2020). Purposive Sampling: Complex or Simple? Journal of Research in Nursing, 25(8), 652–661. https://doi.org/10.1177/1744987120927206
Cao, J., Donato, L., El-Khoury, J. M., Goldberg, A., Meeusen, J. W., & Remaley, A. T. (2024). ADLM Guidance Document on the Measurement and Reporting of Lipids and Lipoproteins. The Journal of Applied Laboratory Medicine, 9(5), 1040–1056. https://doi.org/10.1093/jalm/jfae057
Castelli, W., Anderson, K., Wilson, P., & Levy, D. (1992). Lipids and Risk of Coronary Heart Disease. Annals of Epidemiology, 2(1–2), 23–28. https://doi.org/10.1016/1047-2797(92)90033-m.
Donato, A. J., Machin, D. R., & Lesniewski, L. A. (2018). Mechanisms of Dysfunction in the Aging Vasculature and Role in Age-Related Disease. Circulation Research, 123(7), 825–848. https://doi.org/10.1161/CIRCRESAHA.118.312563
El Khoudary, S. R. (2017). HDL and the Menopause. Current Opinion in Lipidology, 28(4), 328–336. https://doi.org/10.1097/MOL.0000000000000432
Fadhilah, F. R., Sari, A. B., & Aprilianti, A. (2019). The Effect of Test Tube Sterilization from Serum Lipemic Against Levels of Triglyceride GPO-PAP Method. Indonesian Journal of Medical Laboratory Science and Technology, 1(1), 38–43. https://doi.org/10.33086/ijmlst.v.1i1.878
Ference, B. A., Kastelein, J. J., Ray, K. K., Ginsberg, H. N., & Chapman, M. J. (2019). Association of Triglyceride-lowering LPL Variants and LDL-C-Lowering LDLR Variants with Risk of Coronary Heart Disease. JAMA, 321(4), 364–373. https://doi.org/10.1001/jama.2018.20045
Ginsberg, H. N., Packard, C. J., Champman, M. J., Boren, J., Aguilar-Salinas, C. A., & Averna, M. (2021). Triglyceride-rich Lipoproteins and their Remnants: Metabolic Insights, Role in Atherosclerotic Cardiovascular Disease, and Emerging Therpeutic Strategies-a consensus Statement from the European Atherosclerosis Society. European Heart Journal, 42(47), 4791–4806. https://doi.org/10.1093/eurheartj/ehab551
Hong, B. V, Zheng, J. Y., & Zivkovic, A. M. (2023). HDL Function across the Lifespan: From Childhood, to Pregnancy, to Old Age. International Journal of Molecular Sciences, 24(20), 15305. https://doi.org/10.3390/ijms242015305
Kementerian Kesehatan Republik Indonesia. (2022). Penyakit Jantung Penyebab Utama Kematian, Kemenkes Perkuat Layanan Primer. https://kemenkes.go.id/id/penyakit-jantung-penyebab-utama-kematian-kemenkes-perkuat-layanan-primer
Kementerian Kesehatan Republik Indonesia. (2023). Survei Kesehatan Indonesia (SKI) 2023: Tabel 7.29 Prevalensi Penyakit Jantung berdasarkan Diagnosis Dokter pada Penduduk Semua Umur menurut Karakteristik. https://kemenkes.go.id/app_asset/file_content_download/17169067256655eae5553985.98376730.pdf
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Wiklund, O., & Laitinen, P. (2020). Quantifiying Atherogenic Lipoproteins for Lipid-lowering Strategies: Consensus-based Recommendations from EAS and EFLM. Atherosclerosis, 294, 46–61. https://doi.org/10.1016/j.atherosclerosis.2019.12.005
Libby, P., Buring, J. E., & Lewis, E. F. (2019). Atherosclerosis. Nature Reviews Disease Primers, 5(56). https://doi.org/10.1038/s41572-019-0106-z
Nofer, J. R., Kehrel, B., Fobker, M., & Levkau, B. (2002). HDL and Arteriosclerosis: Beyond Reverse Cholesterol Transport. Atherosclerosis, 161(1), 1–16. https://doi.org/10.1016/S0021-9150(01)00651-7
Ouimet, M., Barret, T., & Fisher, E. (2019). HDL and Reverse Cholesterol Transport. Circulation Research, 124(10), 1505–1518. https://doi.org/10.1161/CIRCRESAHA.119.312617
Pownall, H. J., Rosales, C., & Gotto Jr, A. M. (2021). High-density Lipoproteins, Reverse Cholesterol Transport and Atherogenesis. Nature Reviews Cardiology, 18, 712–723. https://doi.org/10.1038/s41569-021-00538-z
Pratama, D., Rahmaditya, F. S., Utama, A. J., Suhartono, R., & Muradi, A. (2023). Risk Factors of Asymptomatic Carotid Artery Disease in Geriatric Evaluated Using Carotid Intima-Media Thickness (IMT) Measurement, the First Indonesian Population Study. Journal of Analogy, 32(02), 095–099. https://doi.org/10.1055/s-0042-1750040
Rosenson, R. S., Brewer, B., Davidson, S., Fayad, Z. A., Fuster, V., Goldstein, J., & Hellerstein, M. (2012). Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport. Circulation, 125(15), 1905–1919. https://doi.org/10.1161/CIRCULATIONAHA.111.066589
Shifa, J.-B., Galicia-Galicia, U., Larrea-Sebal, A., Olaetxea, J. R., & Alloza, I. (2022). Pathophysiology of Atherosclerosis. International Journal of Molecular Sciences, 23(6), 3346. https://doi.org/10.3390/ijms23063346
Syahputri, C. Y., & Ansyari, D. (2026). Hubungan Rasio Low-density Lipoprotein dengan Derajat Keparahan Lesi Aterosklerosis pada Pasien Penyakit Jantung Koroner di Rumah Sakit Umum Haji Medan. GALENICAL: Jurnal Kedokteran dan Kesehatan Mahasiswa Malikussaleh, 5(4). https://doi.org/10.29103/jkkmm.v5i4.29119
Tsompanidi, E. M., Brinkmeier, M. S., Fotiadou, E. H., & Giakoumi, S. M. (2010). HDL Biogenesis and Functions: Role of HDL Quality and Quanty in Atherosclerosis. Atherosclerosis, 208(1), 3–9. https://doi.org/10.1016/j.atherosclerosis.2009.05.034
Virani, S. S., Morris, P. B., Agarwala, A., Ballanyne, C. M., & Birther, K. K. (2021). ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglycerid. Journal of the American Collage of Cardiology, 78(9), 960–993. https://doi.org/10.1016/j.jacc.2021.06.011
World Health Organization. (2010). WHO Guidelines on Drawing Blood: Best Practices in Phlebotomy. Geneva: WHO. https://www.who.int/publications/i/item/9789241599221
World Health Organization. (2023). Best Practices for Collection, Processing, and Storage of Serum Specimens. Geneva: WHO. https://iris.who.int/bitstream/handle/10665/375814/9789240084476-eng.pdf
License
Copyright (c) 2026 Sofiatul Milah, Tuti Suparyati, Bekti Mastiadji

This work is licensed under a Creative Commons Attribution 4.0 International License.

Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.























